Literature DB >> 28394184

Clinical and Molecular Characterization of Infantile-Onset Pompe Disease in Mainland Chinese Patients: Identification of Two Common Mutations.

Xi Chen1, Tingliang Liu1, Meirong Huang1, Jinjin Wu1, Junxue Zhu1, Ying Guo1, Xinyi Xu1, Fen Li1, Jian Wang2, Lijun Fu1,3.   

Abstract

AIMS: We sought to understand the clinical course and molecular defects of infantile-onset Pompe disease (IOPD) among mainland Chinese patients.
MATERIALS AND METHODS: Twenty-five Chinese patients with IOPD were enrolled and clinical data were retrospectively reviewed. The entire coding region of the GAA gene was amplified by polymerase chain reaction and analyzed by direct sequencing.
RESULTS: The median age at symptom onset was 3.4 months (range: 1.0-7.1 months) and 4.9 months (range: 2.7-8.3 months) at diagnosis. Only one patient received enzyme replacement therapy (ERT) and this child survived beyond the age of 2 years. Of the 24 patients not receiving ERT, all, but one patient, died at a median age of 8.3 months (range: 4.0-12.2 months). Thirteen novel and two common GAA mutations were identified in this study. The allelic frequency of c.2662G > T (p.Glu888X) was 23.1% in northern Chinese patients and 4.2% in southern Chinese patients, whereas the allelic frequency of c.1935C > A (p.Asp645Glu) was 20.8% in southern and 3.8% in northern Chinese patients.
CONCLUSIONS: We identified the most common mutations in southern and northern Chinese patients with IOPD.

Entities:  

Keywords:  Pompe disease; acid α-glucosidase; glycogen storage disease type II; lysosomal storage disease; mutation analysis

Mesh:

Substances:

Year:  2017        PMID: 28394184     DOI: 10.1089/gtmb.2016.0424

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  6 in total

Review 1.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

2.  A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease.

Authors:  Diqi Zhu; Jiacong Zhu; Wenjuan Qiu; Benzhen Wang; Lin Liu; Xiaodan Yu; Zhenheng Ou; Guangsong Shan; Jian Wang; Bin Li; Xiaokang Chen; Cong Liu; Zipu Li; Lijun Fu
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

3.  Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database.

Authors:  Kyung Sun Park
Journal:  Mol Genet Metab Rep       Date:  2021-02-26

4.  Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China.

Authors:  Hui-Hui Zhao; Zhi Ma; Zi-Xuan Ying; Feng-Nan Niu; Mao-Tao Luo; Zheng Wang; Xi Cheng; Qian-Qian Zhang; Qi Niu
Journal:  Ann Transl Med       Date:  2021-12

5.  Current status of newborn screening for Pompe disease in Japan.

Authors:  Takaaki Sawada; Jun Kido; Keishin Sugawara; Ken Momosaki; Shinichiro Yoshida; Kanako Kojima-Ishii; Takahito Inoue; Shirou Matsumoto; Fumio Endo; Shouichi Ohga; Shinichi Hirose; Kimitoshi Nakamura
Journal:  Orphanet J Rare Dis       Date:  2021-12-18       Impact factor: 4.123

6.  Late-onset Pompe disease with a novel mutation and a rare phenotype: A case report.

Authors:  Xiaoli Si; Ruoxia Zhang; Shengqiang Yan; Guohua Zhao; Xinzhen Yin; Baorong Zhang
Journal:  CNS Neurosci Ther       Date:  2022-07-07       Impact factor: 7.035

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.